Bastian Dehmel
chairman
management
Oxthera
Sweden
Biography
Chief Medical Officer of OxThera AB. Dr Dehmel has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease at companies like GSK, Novo Nordisk and Amgen. Dr Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgen’s calcimimetic franchise. He brings extensive experience in working with global regulatory agencies and was responsible for FDA and EMA approval of etelcalcetide, and more recently for the orphan pediatric drug approval of cinacalcet by EMA. Dr Dehmel received his medical training in Internal Medicine while at the Charite University in Berlin.
Research Interest
Internal Medicine
